In the massive litigation over alleged side effects from the diabetes drug Avandia, a federal judge has issued a pair of opinions that reject efforts by the drug’s maker, GlaxoSmithKline, to significantly limit the scope of the case.
But GSK also secured some important wins when, in six separate opinions, the same judge dismissed proposed class action suits by former users of the drug who have suffered no side effects but who sought medical monitoring and demanded refunds under state consumer protection law.
